Form 8-K Merck & Co., Inc. For: Feb 04

Go back to Form 8-K Merck & Co., Inc. For: Feb 04

Merck (MRK) PT Lowered to $129 at Goldman Sachs

February 5, 2025 6:35 AM EST

Goldman Sachs analyst Chris Shibutani lowered the price target on Merck (NYSE: MRK) to $129.00 (from $135.00) while maintaining a Buy rating.

The analyst comments "Amidst a backdrop where MRK delivered strong operational performance across the majority of the company's key franchises, the announcement of 2025 guidance, highlighted by the negative impact of the nettlesome dynamics for... More